Delta sleep-inducing peptide
Delta sleep-inducing peptide is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 62568-57-4[1] |
| PubChem CID | 68816[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C35H48N10O15[1] |
| Molecular weight | 848.8 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Delta sleep-inducing peptide is a nonapeptide whose retrieved literature is concentrated in the 1970s and 1980s. A 1986 Peptides paper is an update on the compound and a 1984 Neuroscience and Behavioral Reviews paper is a review of it; both are the most-cited records in the retrieved set.
The retrieved records are animal electrophysiology and distribution work. A 1983 Neuroscience Letters paper reports increased sleep following intracerebroventricular injection, and a 1977 Neuroscience Letters paper reports EEG and motor activity in rabbits. A 1984 Brain Research paper reports evidence that a radiolabelled form crosses the blood-brain barrier, and a 1984 Neuroscience paper reports localisation of neurons containing the immunoreactive peptide.
[3, 4, 5, 6, 7, 8]Reported mechanism
No receptor target is established in the retrieved record set; the records report central effects after direct administration and evidence of blood-brain barrier transit.
[5, 7]Stated in the titles of the cited 1983 Neuroscience Letters and 1984 Brain Research papers.
Targets named in the cited records: central nervous system, target not established.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Delta sleep-inducing peptide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- DSIP
Where this page sits
Research records
Cited research records for Delta sleep-inducing peptide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Kisspeptin-10 — Endocrine and immune signalling peptides
- Thymosin alpha 1 — Endocrine and immune signalling peptides
- Vasoactive intestinal peptide — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Delta sleep-inducing peptide?
Delta sleep-inducing peptide is a nonapeptide whose retrieved literature is concentrated in the 1970s and 1980s. A 1986 Peptides paper is an update on the compound and a 1984 Neuroscience and Behavioral Reviews paper is a review of it; both are the most-cited records in the retrieved set.
Which class is Delta sleep-inducing peptide indexed under?
Delta sleep-inducing peptide is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Delta sleep-inducing peptide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 68816, Delta Sleep-Inducing Peptide. PubChem, National Library of Medicine (2026). pubchem:68816
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:dsip
- Delta-sleep-inducing peptide (DSIP): an update. Peptides (1986). pmid:3550726
- Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and biobehavioral reviews (1984). pmid:6145137
- Increased sleep following intracerebroventricular injection of the delta sleep-inducing peptide in rats. Neuroscience letters (1983). pmid:6688864
- Delta sleep-inducing peptide (DSIP): EEG and motor activity in rabbits following intravenous administration. Neuroscience letters (1977). pmid:19605021
- Evidence that [125I]N-Tyr-delta sleep-inducing peptide crosses the blood-brain barrier by a non-competitive mechanism. Brain research (1984). pmid:6547363
- Localization of neurons containing immunoreactive delta sleep-inducing peptide in the rat brain: an immunocytochemical study. Neuroscience (1984). pmid:6371579
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.